Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMirko LomiSSStefano SodduACAntonio Curti

Discussion

Loading...

Member takes

Overview

Phase 2 trial tested venetoclax and decitabine, improving complete response in myeloproliferative neoplasm-blast patients, suggesting further exploration is viable.

Key Points

  • Complete response rate improved with venetoclax and decitabine treatments in myeloproliferative neoplasm-blast patients, indicating efficacy.
  • The trial met its primary endpoint with a notable event free survival rate of 32.8% after 12 months.
  • Participation included 101 myeloproliferative neoplasm-blast patients from 28 centers, ensuring diverse representation.
  • Safety signals were observed, with treatment-related adverse events like neutropenia needing monitoring for effective clinical use.

Cite This Study

Lomi et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d41fhttps://doi.org/10.1182/blood-2025-1025
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure2025
  2. 2Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025
  3. 3Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine2025 · 1 citations
  4. 4Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial2025 · 2 citations
  5. 5Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial2025